Fresh guidance from the Food and Drug Administration has heralded yet another change for biosimilar interchangeability in the US, with the agency suggesting that analytical and clinical data will suffice to support a determination of interchangeability, rather than applicants needing to conduct separate switching studies.
In the draft guidance, "Considerations in Demonstrating Interchangeability With a Reference Product: Update," the agency has set out a...